Niacin

Recommended test

Triglycerides (lipid panel)

Niacin is one of the most studied nutrients for lipid management, historically used to lower triglycerides and LDL while raising HDL. It works primarily in the liver, reducing the production of VLDL — the particle that carries triglycerides into circulation.

Common forms & typical benefits

Which form, and why

What the research says

Evidence by outcome

The honest summary here mirrors homocysteine: niacin reliably and substantially improves the lipid numbers themselves. But in the one large outcomes trial that actually tested whether that translates to fewer heart attacks and strokes in people already on a statin, it didn't. That doesn't mean niacin is useless — the AIM-HIGH population was already well-treated with statins, which may have left little additional room for benefit — but it's a meaningful caveat against assuming "better labs" automatically means "better outcomes."

Dosages used in studies

What the research actually tested

Note: the 100 mg dose used in practice here is well below the doses used in the triglyceride/cholesterol trials above — it's chosen for tolerability, not to replicate the exact lipid-lowering effect sizes from those higher-dose studies.

Note: doses at and above 1,000 mg/day are where liver enzyme monitoring becomes important — this isn't a "more is always fine" supplement.

Safety notes & high-dose risks

What to watch for

• Flushing: warmth, redness, tingling — the most common side effect, most intense with IR at first dose, typically fading within 1-2 weeks of consistent use. Not dangerous, but can be uncomfortable enough that people stop taking it.
• Liver enzyme elevation: a real risk at doses of 1,000 mg/day and above, especially with older sustained-release formulations — liver enzymes should be monitored before starting and periodically during treatment.
• In practice, this is used here at a 100 mg dose — well below the 1,000 mg+ range where liver risk becomes a real concern, and considerably more tolerable for most people than higher research doses.
• Raises uric acid — direct overlap with the Uric Acid marker in this panel. Niacin can worsen gout or trigger a flare in people with a history of gout or elevated uric acid; this is worth knowing if uric acid is already a marker being watched.
• Can raise blood sugar — anyone with diabetes or insulin resistance should monitor glucose more closely when starting or adjusting the dose.
• Interacts with blood thinners: can modestly increase prothrombin time; caution around surgery or anticoagulant use.

Additional notes

Worth knowing

• Reducing flushing: taking with food, starting at a low dose and titrating up slowly, and avoiding hot showers/alcohol around dosing time all help. Some people use aspirin beforehand under provider guidance, though this adds its own GI-risk tradeoff.
• Timing: ER forms are typically taken at night specifically to minimize side-effect burden during waking hours.
• Ties to the broader panel: since niacin affects uric acid and blood sugar as well as lipids, it's a good example of why triglycerides aren't treated in total isolation here — the choice of niacin (versus, say, berberine) for a given person depends on the whole picture, not just the triglyceride number.
• Room to titrate if needed: the 100 mg starting point can always be increased if the response isn't sufficient on its own. But niacin isn't used in isolation here — addressing the other overlapping pathways at the same time often allows real biomarker improvement at this lower, more tolerable dose, rather than needing to push into the higher-risk range to get results.
• Retesting: lipid panel plus liver enzymes and uric acid, roughly 8-12 weeks after starting or changing dose.
• Form matters enormously here — more than with most supplements on this site. Niacinamide and "no-flush" inositol hexanicotinate will not produce the lipid effects described above.